24-Apr-2014 - Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross...
10-Apr-2014 - Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst...
03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.
02-Apr-2014 - Argenta and BioFocus will add approximately $70m (€51m) to Charles River Laboratories’ 2014 revenues, the firm and an analyst say.
26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
24-Mar-2014 - Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.
20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
14-Mar-2014 - Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.
13-Mar-2014 - In an exclusive interview, Patheon Executive Mike Lehmann talks DSM integration, further growth and how consolidation amongst CMOs may be driving strategic alliances with pharma.
13-Mar-2014 - Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.
10-Mar-2014 - In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.
26-Feb-2014 - DSM has reported modest growth in its pharma business as a shareholders advisory firm comes out in favour of the upcoming merger with Patheon.
24-Feb-2014 - CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.
24-Feb-2014 - Icon says it intends to continue its M&A strategy focusing on capabilities, geographies and technologies as it reports a robust 2013.
19-Feb-2014 - Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.
12-Feb-2014 - Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service...
03-Feb-2014 - CROs CTI Trial and Clinical Consulting recently acquired Community Research, David Blume, managing director of Edgemont Capital, told us.
30-Jan-2014 - Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.
30-Jan-2014 - Asia’s leading small-molecule CRO GVK BIO will acquire the capital stock of US-based CRO Aragen Bioscience.
20-Jan-2014 - Strategic relationships with both big pharma and mid-tier firms will drive future growth, says Charles River laboratories (CRL).
14-Jan-2014 - Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.
09-Jan-2014 - Merck Millipore has sold its Discovery and Development Solutions (DDS) Business to Eurofins saying it was unable to fully support.
08-Jan-2014 - Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.
02-Jan-2014 - Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business.
19-Dec-2013 - A private equity investor has sold its stake in CRO Chiltern leading to a restructured ownership the firm says will encourage expansion.